UCB highlighted its 2025 achievements, and reiterated its recently upgraded FY25 guidance (5 December 2025). This was the company's second guidance upgrade in 2025 and shows that UCB's commercial momentum continues its upward trajectory supported by its 5 key growth drivers, including lead product Bimzelx which saw strong momentum in HS. This is further supported by Bimzelx reaching over 100K patients worldwide. Looking ahead, Bimzelx' expanded access in 2026 to include 36m additional covered li...
AB InBev: $3bn in the can; Aedifica: €108.5m investments at a 6-7% yield; Kinepolis: December US box office revenue down 2%, France visitors up 1%, Avatar below expectations; TomTom: Starting the year with CES fireworks; WDP: €58m investment in Le Havre and €35m disposal in Liège.
For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...
Two Directors at Anheuser-Busch In Bev SANV sold 256,000 shares at between 51.810EUR and 52.160EUR. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...
UCB presented detailed results of the positive phase 3 GEMZ study with Fintepla in CDKL5 deficiency disorder (CDD). The drug showed an estimated 52.7% median reduction in countable motor seizure frequency (CMSF) compared with placebo during a 14 week titration and maintenance period and a favourable safety profile. We view this as highly encouraging in this refractory epilepsy population. Given the infantile onset of CDD, we will be curious to see as of which age, patients could be included in t...
A director at EVS Broadcast Equipment SA sold 9,750 shares at 35.120EUR and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.